Gilteritinib in R/R AML

Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the use of gilteritinib, a tyrosine kinase inhibitor, in relapsed/refractory (R/R) FLT3m+ acute myeloid leukemia (AML) patients. Dr Daver discusses the results of the ADMIRAL study (NCT02421939), evaluating gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML, as well as an ongoing study evaluating gilteritinib in combination with azacitidine. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).